Tissue microarrays in diffuse large B-cell lymphomas: Are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?

D. Laszlo, G. Pruneri, G. Andreola, D. Radice, L. Calabrese, P. R. Rafaniello, L. Nassi, S. Sammassimo, A. Alietti, A. Agazzi, A. Vanazzi, G. Martinelli

Research output: Contribution to journalArticle

Abstract

Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.

Original languageEnglish
Pages (from-to)417-424
Number of pages8
JournalInternational Journal of Surgical Pathology
Volume19
Issue number4
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphoma
B-Lymphocytes
Germinal Center
Anthracyclines
Oligonucleotide Array Sequence Analysis
Transcriptome
Disease Progression
Immunohistochemistry
Prospective Studies
Antigens
Drug Therapy
Survival

Keywords

  • immunohistochemistry
  • non-Hodgkin's lymphomas
  • prognostic factors
  • tissue microarray

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

@article{c4ef1c45032f466b80dc9280df70a774,
title = "Tissue microarrays in diffuse large B-cell lymphomas: Are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?",
abstract = "Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48{\%}) were identified as GCB and 55 (52{\%}) as non-GCB. The overall response rate was 89{\%} (94/105), with 62 (59{\%}) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3{\%} and 66.6{\%} for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.",
keywords = "immunohistochemistry, non-Hodgkin's lymphomas, prognostic factors, tissue microarray",
author = "D. Laszlo and G. Pruneri and G. Andreola and D. Radice and L. Calabrese and Rafaniello, {P. R.} and L. Nassi and S. Sammassimo and A. Alietti and A. Agazzi and A. Vanazzi and G. Martinelli",
year = "2011",
month = "8",
doi = "10.1177/1066896909345596",
language = "English",
volume = "19",
pages = "417--424",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Tissue microarrays in diffuse large B-cell lymphomas

T2 - Are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?

AU - Laszlo, D.

AU - Pruneri, G.

AU - Andreola, G.

AU - Radice, D.

AU - Calabrese, L.

AU - Rafaniello, P. R.

AU - Nassi, L.

AU - Sammassimo, S.

AU - Alietti, A.

AU - Agazzi, A.

AU - Vanazzi, A.

AU - Martinelli, G.

PY - 2011/8

Y1 - 2011/8

N2 - Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.

AB - Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.

KW - immunohistochemistry

KW - non-Hodgkin's lymphomas

KW - prognostic factors

KW - tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=80052391478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052391478&partnerID=8YFLogxK

U2 - 10.1177/1066896909345596

DO - 10.1177/1066896909345596

M3 - Article

C2 - 19793830

AN - SCOPUS:80052391478

VL - 19

SP - 417

EP - 424

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 4

ER -